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Abstract
Background: Many young people experiment with cannabis, yet only a subgroup progress to dependence suggesting
individual differences that could relate to factors such as genetics and behavioral traits. Dopamine receptor D2 (DRD2) and
proenkephalin (PENK) genes have been implicated in animal studies with cannabis exposure. Whether polymorphisms of
these genes are associated with cannabis dependence and related behavioral traits is unknown.
Methodology/Principal Findings: Healthy young adults (18–27 years) with cannabis dependence and without
a dependence diagnosis were studied (N = 50/group) in relation to a priori-determined single nucleotide polymorphisms
(SNPs) of the DRD2 and PENK genes. Negative affect, Impulsive Risk Taking and Neuroticism-Anxiety temperamental traits,
positive and negative reward-learning performance and stop-signal reaction times were examined. The findings replicated
the known association between the rs6277 DRD2 SNP and decisions associated with negative reinforcement outcomes.
Moreover, PENK variants (rs2576573 and rs2609997) significantly related to Neuroticism and cannabis dependence. Cigarette
smoking is common in cannabis users, but it was not associated to PENK SNPs as also validated in another cohort (N = 247
smokers, N = 312 non-smokers). Neuroticism mediated (15.3%–19.5%) the genetic risk to cannabis dependence and
interacted with risk SNPs, resulting in a 9-fold increase risk for cannabis dependence. Molecular characterization of the
postmortem human brain in a different population revealed an association between PENK SNPs and PENK mRNA expression
in the central amygdala nucleus emphasizing the functional relevance of the SNPs in a brain region strongly linked to
negative affect.
Conclusions/Significance: Overall, the findings suggest an important role for Neuroticism as an endophenotype linking
PENK polymorphisms to cannabis-dependence vulnerability synergistically amplifying the apparent genetic risk.
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dependent on cannabis at a young age though cannabis typically
has a delayed progression to dependence as compared to other
drugs of abuse [5]. This difference in individual vulnerability has
added to the heated debate as to whether cannabis is benign and
should be legalized or a harmful drug whose status as an illegal
substance should be maintained. Irrespective of the debate,
cannabis-dependent individuals greatly outnumber those reporting
dependence on other more addictive substances [3] and cannabis

Introduction
Marijuana (Cannabis sativa) is the illicit drug most commonly
used in most Western societies [1–3]; it was consumed by at least
11.5% of individuals 12 years or older in the United States in
2010, even more so among teenagers (14%) and young adults
(30%) [3]. Despite its common use, only a subset of teens and
young adults using cannabis (25.4% and 19.0%, respectively)
progress to abuse or dependence [4]. Such individuals become
PLoS ONE | www.plosone.org
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daily cigarette use (Table 1). Among controls, 66.0% reported
cannabis use at least once.

dependence carries a heavy burden, as it is associated with
detrimental consequences on health [6]. Important research efforts
have focused on cannabis use in association with specific disorders,
such as psychosis, and among clinical populations with substantial
comorbid psychopathology; but the larger cannabis-dependent
population and the potential relevance of genetics and behavioral
traits, such as reward sensitivity and neuroticism-anxiety, have
been understudied.
Similar to other addictions, cannabis dependence is a complex
disorder; thus, genetic interactions with factors such as behavioral
traits and environmental conditions could contribute to addiction
vulnerability. A growing number of family, twin and adoption
studies have shown that cannabis-use disorder is influenced by
heritability (30–80%) [7–15]. However, specific genetic determinants and behavioral factors remain unknown. In this study, we
sought to examine factors relevant to cannabis-dependence risk by
evaluating genetic polymorphisms of neural systems implicated in
the actions of cannabis and to behavioral traits associated with
addiction vulnerability.
Converging evidence obtained from animal and human brain
studies has shown that early cannabis exposure selectively alters
dopamine receptor D2 (DRD2) and proenkephalin (PENK)
expression in the mesocorticolimbic system, disturbances that
persist into adulthood and modulate drug-seeking behavior later in
life [16,17]. The sensitivity of striatal PENK and DRD2 expression
to delta-tetrahydrocannabinol (THC) raises the question as to
whether genetic polymorphisms of these genes could in turn be
associated with cannabis dependence. Moreover, the fact that
these genes in the striatum are specifically colocalized in
striatopallidal neurons, a critical component of the neuronal
circuitry underlying inhibitory control, may have important
implications to addiction vulnerability. While it is unknown
whether genetic disturbances of DRD2 or PENK could contribute
to cannabis dependence, behavioral studies have demonstrated
that SNPs in DRD2 predict specific behavioral traits pertaining to
reward sensitivity, inhibitory control and affect [18–20], endophenotypes known to be involved in addiction vulnerability. As
such, we focused a priori on whether individual genetic differences
of the DRD2 and PENK genes associate with cannabis dependence
and explored the possible mediation or moderation of intermediate endophenotypes in the genetic associations. Given the current
lack of information as to the functional relevance of the PENK
SNPs, we also assessed potential genotype relationships to mRNA
expression levels in the postmortem human brain from another
population sample.

Description of Procedures Undertaken
Subjects were evaluated to obtain information regarding current
health and sociodemographic characteristics. Exclusion of subjects
with major psychiatric disorder was based on the Mini International Neuropsychiatric Interview [21]. Substance-abuse and
-dependence diagnoses were determined using the Structured
Clinical Interview for DSM-IV [22]. Exclusion criteria included
major neurological/medical illness or taking systemic medication;
history of head injury with loss of consciousness, neurological or
cardiovascular disease, traumatic brain injury or any other
condition that is likely to affect brain function; pregnancy;
diagnosis or history of bipolar I or II disorder, ADHD, psychosis,
pervasive developmental disorder, major affective disorder, motor
tics or Tourette’s Syndrome, or seizure disorders; current or past
use of psychotropic medication.
The cognitive probabilistic learning task involves a training
phase in which participants learn to discriminate the feedback
probabilities (positive feedback: green check mark; negative
feedback: red cross) associated with different pairs of symbolic
stimuli [18]. Participants learn from trial-and-error that symbol A
was being rewarded with positive feedback in 80% of the trials,
whereas symbol B was being rewarded in 20%. The distribution of
positive-feedback probabilities for other pairs range from 70%
versus 30% for Pair C–D, and 60% versus 40% for Pair E–F.
Feedback is given for each trial. At the end of the training phase
(128 trials), participants should learn that symbol A is the most
favorable choice and the one most likely to get positive feedback,
whereas symbol B is the least favorable one and should be avoided.
During the testing phase, symbols A and B are paired with the
other four symbols to create 8 new pairs for a total of 96 trials, and
no feedback is given during the test. The results were tallied
according to the proportions of trials in which symbol A was
chosen over other symbols or symbol B was avoided when paired
with other symbols. Performance on ‘’Choose A’’ pairs was used as
a measure of positive-reinforcement learning, whereas performance on ‘’Avoid B’’ pairs reflected negative-reinforcement
learning.
A version of the ‘‘stop-signal’’ Go/NoGo task was then
administered to measure response inhibition. Subjects were asked
to discriminate between letters ‘‘X’’ and ‘‘O’’ as quickly and
accurately as possible. One third of the time they were told to
withhold their responses for the ‘‘NoGo’’ trial when they heard
a ‘‘stop’’ signal tone (a clear sound) presented at a variable delay
after the letter was displayed. A staircase variation of the stopsignal-delay was used to keep the commission error (CE) rate at
,50% for the ‘‘stop’’ trials, in line with previous studies [23,24].
Stop-signal reaction time (SSRT), the mean length between the
stop signal tone and the mean reaction time, measured the
capacity of response inhibition.
Both tasks were administered approximately 2 hours after the
subject’s arrival at the study site. Subjects were instructed to
abstain from using alcohol or drugs (except nicotine) on the day of
the testing session, which was not conducted if the participant
showed any evidence of acute intoxication.
Positive and negative affective states were assessed with the
(Positive and Negative Affect Schedule) PANAS [25] and
personality traits were studied with the (Zuckerman-Kuhlman
Personality Questionnaire) ZKPQ [26]. To confirm self-reported
drug-use information, urine samples were screened for cannabis,
along with other illicit drugs; all subjects also underwent
a breathalyzer. None of the subjects screened positive for alcohol

Methods
Participants
Two hundred and eleven individuals were screened to enroll
100 participants meeting all eligibility criteria. The participants
were between the ages of 18–27 and consisted of 50 controls and
50 subjects with a lifetime cannabis-dependence diagnosis (74.0%
with current and 26.0% with past cannabis dependence). Eligible
subjects were healthy males and females with no history of major
psychiatric or medical disorders and no current or sustained past
(more than one month) psychotropic medication. The recruitment
of otherwise normal, non-treatment-seeking subjects aimed to
have a study sample representative of the general cannabis
population, as opposed to other cannabis-abuse populations with
psychopathology and neuropsychiatric comorbidities. Cannabisdependent subjects and controls had similar racial breakdowns
and only differed in the percentage of Hispanic participants and
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Table 1. Sociodemographic characteristics of the participants.

Total
N = 100 % (N)

Cannabis dependent subjects
N = 50 % (N)

Controls
N = 50 % (N)

Male

67.0 (67)

74.0 (37)

60.0 (30)

Female

33.0 (33)

26.0 (13)

40.0 (20)

Age, mean (SD)

22.65 (2.78)

22.54 (2.57)

22.76 (3.00)

Married

9.0 (9)

10.0 (5)

8.0 (4)

Single or widowed

91 (91)

90.0 (45)

92.0 (46)

Hispanic or Latino*

41.0 (41)

52.0 (26)

30.0 (15)

African American

30.0 (30)

26.0 (13)

34.0 (17)

Caucasian

25.0 (25)

22.0 (11)

30.0 (15)

Asian

3.0 (3)

0.0 (0)

6.0 (3)

Characteristics
Sex

Marital status

Ethnic background

Education
High school degree, GED, or higher

93.0 (93)

90.0 (45)

96.0 (48)

Less than high school degree or GED

7.0 (7)

10.0 (5)

4.0 (2)

Working status
Working or studying

73.0 (73)

66.0 (33)

80.0 (40)

Unemployed

27.0 (27)

34.0 (17)

20.0 (10)

Lifetime cannabis use (yes)

83.0 (83)

100.0 (50)

66.0 (33)

Age at initiation of cannabis use
(mean +/2 SD)

16.01 (2.47)

15.66 (2.41)

16.55 (2.50)

Daily nicotine use***

29.0 (29)

54.0 (27)

4.0 (2)

Asterisk indicates significant difference between cannabis dependent and controls subjects. SD = Standard deviation.
*p,0.05;
***p,0.001.
doi:10.1371/journal.pone.0039243.t001

In situ hybridization was performed (on 20 mm-thick cryosections as previously described to measure PENK mRNA expression
levels) [29,30]. The PENK riboprobe was an EcoRI/Pvu 792 bp
fragment complementary to the full coding region of the PENK
human gene [31]. Briefly, brain sections were hybridized with
206103 CPM/ ml [35S]-aUTP PENK riboprobe solution overnight
at 55uC and following post-hybridization washes, exposed to
Kodak Biomax MR film for 5 days. Optical density values
measurements were taken over subregions of the striatum and the
central amygdala and the values converted to DPM (disintegrations per minute)/mg by reference to co-exposed C14 standards
(American Radiolabeled Chemicals, Inc., St. Louis, MO). DPM/
mg values from duplicate slides were averaged.

or any other drug than cannabis. 86.0% of the cannabis
dependent individuals were positive for cannabis.
Genotype for cannabis dependence and control subjects was
determined using an ABI 7900HT available at the Mount Sinai
Quantitative PCR Shared Resource Facility. DRD2 SNPs: TaqIA
(rs1800497) is located ,10 kb downstream of the DRD2 and
affects striatal DRD2 receptor density [27], rs6277 and rs1076560
are associated with DRD2 expression and cognitive/attentional
performance [28]. PENK SNPs: rs2576573, rs2609997 and
rs6474063 were chosen based on pairwise linkage disequilibrium
(LD) relationships (r2) of an r2 threshold of 0.8 and on haplotype
data (www.hapmap.org) showing a minimum allele frequency of
0.10 in the population. The call rate was 100% and all genotypes
examined conformed to Hardy-Weinberg equilibrium.
Fresh-frozen striatal and amygdala specimens were obtained
from normal adult Caucasian subjects without head trauma from
our brain bank collection [29] (collected at the Department of
Forensic Medicine at Semmelweis University, Hungary). The
specimens were collected under the guidelines approved by the
local Human Ethical Committee within 24 hrs after death. The
demographic characteristics of total subjects (N = 16) were:
36.863.0 years old; 13 males/3 females, 6.7260.06 brain pH;
postmortem interval 20.961.7 hrs; cause of death being cardiac
failure (N = 12), viral infection (N = 2), pulmonary embolus (N = 1),
electric shock (N = 1). Striatal samples were only available for 14 of
the specimens.

PLoS ONE | www.plosone.org

Ethics
All participants in this study gave written informed consent;
Mount Sinai School of Medicine Institutional Review Board
approved the study.

Statistical Analysis
Independent t-tests and Chi-square tests were used to compare
cannabis-dependent and control subjects according to sociodemographic characteristics. Association between genotype, behavioral traits and cannabis-use outcomes were analyzed by
ANOVA and Pearson correlation, while group (based on
cannabis-dependence diagnosis) and gene x group interaction
effects were calculated using a general linear model. For each
3
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whole sample. Inhibitory control as measured by SSRT was not
modulated by any of the SNPs examined.
Evaluation of performance in the cognitive probabilistic
learning tasks revealed that cannabis-dependent subjects and
controls did not differ in their overall accuracy in the training
phase (t = 0.15, p = 0.88) or during the testing session for reaction
time (t = 0.075, p = 0.94). There was also no significant group
difference for accuracy on either Choose A or Avoid B pairs
(t = 0.066, p = 0.95, and t = 0.28, p = 0.78, respectively). On the
stop-signal Go/NoGo task, the two groups also showed similar
overall accuracy (t = 0.22, p = 0.83) and their SSRT did not differ
significantly (t = 1.23, p = 0.22).
In evaluating genetic differences between cannabis and control
subjects in regard to the DRD2 and PENK genes, it was observed
that several DRD2 and PENK SNPs studied modulated cannabisdependence outcomes (Table 2). A strong association was evident
between the PENK SNP rs2576573 and cannabis-dependence
diagnoses; 61.7% of cannabis-dependent subjects were A/G
carriers, compared with 29.2% of controls (p,0.001). Similar
findings were apparent for the other PENK SNP rs2609997 and
the DRD2 SNP rs6277. Only the association between cannabis
dependence and the two PENK SNPs remained significant after
Bonferroni correction.
Subjects who were grouped based on a lifetime cannabisdependence diagnosis (n = 50) or as controls (n = 50) differed in
relation to affect and temperamental traits as reported on the
PANAS and ZKPQ. Our study focused on Impulsive Risk Taking
and Neuroticism-Anxiety subscales of the ZKPQ which we used as
a temperamental proneness to poor inhibitory control as well as
negative emotional traits (negative affect and anxiety), respectively.
Cannabis-dependent individuals reported more negative affect on
the PANAS (p = 0.013) and higher scores on the Neuroticism
(p = 0.004), Impulsivity (p = 0.0002) and Aggression-Hostility
(p = 0.0008) subscales of the ZKPQ, as well as a lower mean
score on Activity-Energy (p = 0.049). Significant associations were
detected between genetic polymorphisms and temperamental
traits. Neuroticism was associated with rs6277 (p,0.05),
rs2576573 (p,0.01) and rs2609997 (p,0.05), as shown in
table 3. There was a significant cannabis-dependence group effect
(F = 6.2, p = 0.02) and SNP x cannabis-dependence interaction
(F = 4.7, p = 0.03) for the PENK SNP rs2609997, as this SNP was
significantly associated with Neuroticism in cannabis-dependent
subjects (p,0.05), but not in control subjects (p = 0.8; Fig. 2).
None of the SNPs were associated with Impulsivity.
Mediation models were subsequently examined to determine
whether behavioral traits mediated the genetic association with
cannabis outcomes. Neuroticism was a notable mediator of the
association between rs6277, rs2576573, and rs2609997 and
cannabis dependence; 15.3% to 19.5% association between the
gene and cannabis dependence was explained by Neuroticism.
None of the inhibitory control, reward learning or impulsive
temperamental traits met criteria as mediators of the associations
between any SNPs and cannabis dependence outcomes. We
further examined the potential interaction (moderation) effect of
having a genetic and temperamental risk focusing on Neuroticism,
which was the most strongly associated with cannabis dependence.
We categorized Neuroticism by median score into high and low
Neuroticism groups and evaluated four groups: high genetic risk
and high Neuroticism; high genetic risk and low Neuroticism, low
genetic risk and high Neuroticism; neither risk (reference group).
Figure 3 shows a clear evidence for additive interaction with AP
being 0.67 (95% CI, 0.62–0.72), indicating 67% increased risk is
due to synergy. Relative to the reference group, those with high
Neuroticism (OR = 1.3, p = .85) or an at-risk SNP (PENK

SNP, polymorphisms that were significantly associated with
phenotype were evaluated for genotyping patterns of variants
using the Fisher’s exact test. A reduction in unstandardized beta of
.10% on cannabis dependence by the genetic factor after the
potential mediator (e.g., Neuroticism) was included in the model,
and was considered to be appreciably different and reported as
a partial mediator. Additive interaction was evaluated based on
the Rothman ‘‘index of synergism.’’ The presence/absence of an
additive interaction was examined using an index, attributable
proportion due to interaction (AP) and the 95% confidence
interval (CI) estimated based on the Hosmer-Lemeshow CI
estimation of interaction. AP exceeding zero indicates increased
risk due to the two risk factors. Thus, the 95% CI for an AP that
does not include a value of zero indicates statistical significance.
To account for testing of multiple SNPs as predictors of cannabis
dependence, we used the Bonferroni correction and, accordingly,
all the tests used a 2-tailed a = 0.017 (0.05/3) significance level for
each gene.
The mRNA expression (DPM/mg) data was normalized using
natural logarithm. General linear stepwise regression analysis was
used to evaluate genotype group differences with covariates: e.g.,
age, postmortem interval, brain pH, and sex. Statistical evaluations were assessed by using JMP 6.1 (SAS Institute, Cary, NC,
USA) software.

Results
Previous behavioral studies have reported that DRD2 SNPs
predict avoidance-based decisions in healthy subjects [18,19,32].
Results from the current population confirmed that negative
reinforcement learning linked with the ability to avoid maladaptative choices was associated with the DRD2 rs6277 SNP (Fig. 1).
There was an overall significant genotype difference, but there was
no group or group x genotype interaction on Avoid B behavior.
Subjects carrying the rs6277 A allele performed significantly better
than G/G homozygous subjects on Avoid B pairs (p,0.005), but
not for the positive Choose A performance. Other DRD2 and
PENK SNPs examined did not influence reward learning
performance in cannabis-dependent or control subjects, or in the

Figure 1. DRD2 SNP rs6277 in relation to the accuracy of
choose A (positive reinforcement) and Avoid B (negative
reinforcement) performance. ***, p,0.005 between the genotypes.
doi:10.1371/journal.pone.0039243.g001
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Table 2. Genotype distributions in cannabis dependent
subjects and controls for the SNPs studied.

Table 3. Neuroticism score in relation to SNPs studied.

SNPs
SNPs

Genotype

D2 rs6277*

D2 rs1076560

D2 rs1800497

PENK rs2609997**

A/A

2 (4.0)

10 (20.0)

A/G

22 (44.0)

15 (30.0)

G/G

26 (52.0)

25 (50.0)

A/A

1 (2.0)

1 (2.0)

A/C

13 (26.0)

14 (28.0)

C/C

36 (72)

35 (70.0)

A/A

5 (10.0)

3 (6.0)

A/G

16 (32.0)

23 (46.0)

G/G

29 (58.0)

24 (48.0)

C/C

6 (12.0)

4 (8.0)

C/T

25 (50.0)

12 (24.0)

T/T

19 (38.0)

34 (68.0)

PENK rs2576573*** A/A

PENK rs6474063

Cannabis dependent Controls
N (%)
N (%)

6 (12.8)

4 (8.3)

A/G

29 (61.7)

14 (29.2)

G/G

12 (25.5)

30 (62.5)

C/C

0 (0.0)

3 (6.0)

C/T

15 (30.0)

13 (26.0)

T/T

35 (70.0)

34 (68.0)

D2 rs6277*

D2 rs1076560

D2 rs1800497

PENK rs2609997*

PENK rs2576573**

PENK rs6474063

Genotype

Neuroticism (SD)

A/A

3.50 (2.68)

A/G

6.62 (4.78)

G/G

4.63 (4.23)

A/A

9.00 (8.49)

A/C

5.44 (4.56)

C/C

5.04 (4.27)

A/A

5.75 (5.12)

A/G

4.87 (4.40)

G/G

5.42 (4.37)

C/C

4.50 (3.69)

C/T

6.92 (5.01)

T/T

4.19 (3.75)

A/A

4.50 (3.69)

A/G

6.98 (4.86)

G/G

3.67 (3.52)

C/C

5.33 (4.73)

C/T

6.21 (4.49)

T/T

4.83 (4.37)

doi:10.1371/journal.pone.0039243.t003

N = 100, except for PENK rs2576573 for which 5 subjects were excluded due to
genotyping failure. Asterisks indicate a significant SNP x group (cannabis
dependence diagnosis vs. control) effect.
*p,0.05,
**p,0.01,
***p,0.001, uncorrected.
doi:10.1371/journal.pone.0039243.t002

rs2609997; OR = 1.8, p = .26) did not have notable increased risk,
but those with high Neuroticism and the at-risk SNP had an over
9-fold increased clinical diagnosis of cannabis dependence
(OR = 9.2, p = .0007). A similar additive interaction was detected
for the PENK rs2576573 [AP = 0.72, (95% CI, 0.58–0.86)].
Relative to the reference group, those with both at-risk SNP
(PENK rs2576773) and high Neuroticism had an over 8-fold
increased clinical diagnosis of cannabis dependence (OR = 8.35,
p = .001), compared to those with only Neuroticism (OR = 0.93,
p = .99) or the at-risk SNP (OR = 2.41, p = .27). It was not possible
to study the DRD2 rs6277 SNP due to the high overlap between
high Neuroticism and subjects with the G allele.
Given that most cannabis-dependent subjects smoked cigarettes
and the documented differences between cigarette smokers and
non-smokers in terms of Neuroticism [33], we evaluated whether
nicotine use may be the factor driving behavioral specificity in
cannabis-dependent subjects. In our sample, there were no
differences as to temperamental traits, affect, reward learning,
inhibitory control and SNPs between cannabis-dependent subjects
who smoked cigarettes daily compared to those who did not. To
further address this issue, we also examined PENK SNPs in
another population (homogenous Caucasian Greek army conscripts; Table 4) in which personality traits had been obtained
(N = 559, 247 smokers and 312 non-smokers; mean age = 23.4
years), as described previously [34]. Cigarette smoking without
cannabis use was associated with Neuroticism (p = 0.02), but it was
not significantly related to the PENK SNPs (rs2609997, rs2576573).
Interestingly, although the cannabis-dependence diagnosis was not
assessed in this population, an additive-interaction effect between
PLoS ONE | www.plosone.org

Figure 2. Neuroticism scores in relation to PENK rs2609997
SNP among controls, and in cannabis-dependent subjects.
*, p,0.05 between the genotypes.
doi:10.1371/journal.pone.0039243.g002

Neuroticism and both PENK SNPs predicted the history of
cannabis use (rs2609997, p = 0.01; rs2576573, p = 0.02).
Very limited information is known about the neurobiological
relevance of mutations of the PENK gene. Thus, given that the
current PENK SNPs studied are within noncoding regions of the
gene, we examined their potential relationship to PENK mRNA
expression levels in the postmortem striatum and amygdala,
regions highly implicated in emotional regulation in normal
human subjects. PENK mRNA is expressed throughout the
striatum and predominantly in the central nucleus of the
amygdaloid complex (Figure 4). A strong significant association
5
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Figure 3. Odds ratio (OR) of the association between Neuroticism and PENK SNPs rs2609997 (black bars)/rs2576573 (gray hatched
bars) in relation to cannabis dependence; adjusted for gender and age. High risk genotype = C/C + C/T for rs2609997 or A/A + A/G for
rs2576573; low risk genotype = T/T for rs2609997 or G/G for rs2576573. ***p,0.01; ****p,0.001.
doi:10.1371/journal.pone.0039243.g003

was detected between the PENK SNPs and mRNA expression in
the central amygdala (rs2576573 F1,15 = 13.43, p = 0.003). Overall, control subjects with the A allele of the rs2576573 SNPs had
higher PENK expression (Figure 4). In the striatum, PENK
mRNA expression was significantly influenced by age and only
a trend-genotype effect was detected in the nucleus accumbens
core (F1,10 = 3.778, p = 0.084). A gene-dose effect was also evident
for the rs2609997 SNP in the central amygdala (F2,15 = 5.577,

p = 0.018) with C/C subjects having higher PENK mRNA
expression, but there were few homozygous subjects, so this SNP
could not be fully evaluated in the postmortem population.

Discussion
Although cannabis does not have high abuse liability as other
drugs, it is clear that some individuals are more susceptible to

Table 4. Sociodemographic characteristics and genotype distribution for the proenkephalin SNPs studied in the Caucasian Greek
cohort.

Smokers
(N = 247)

Non-smokers
(N = 312)

P value

Age, mean (SD)

23.72 (4.13)

23.08 (4.47)

0.084

Education, mean (SD)

15.62 (2.68)

15.23 (2.85)

0.097

Neuroticism score [Eysenck Personality
Questionnaire] (SD)

10.83 (4.9)

9.78 (5.07)

0.005

SNPs

Genotype

Smokers
N (%)

Non-smokers
N (%)

rs2576573#

G/G

83 (33.6)

103 (33.0)

G/A

117 (47.4)

137 (43.9)

A/A

47 (19.0)

71 (22.8)

A/A

76 (30.8)

93 (29.8)

G/A

120 (48.6)

140 (44.9)

G/G

50 (20.2)

76 (24.4)

rs2609997##

All subjects were healthy control males from a highly homogenous Caucasian population of army conscripts. Minor allele frequency was 0.44 (rs2576573) and 0.46
(rs2609997). Hardy-Weinberg equilibrium for the full population: x2 = 3.2 (p = 0.07) rs2576573 and 1.8 (p = 0.18) for rs2609997. SD: standard deviation.
one non-smoker with missing genotype;
##
one smoker and two non-smokers with missing genotype.
doi:10.1371/journal.pone.0039243.t004
#
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Figure 4. PENK mRNA distribution (A) and expression levels (B) in the amygdala of control subjects with the A/G and G/G genotype
for the rs2576573 SNP. Expression levels (mean 6 SEM) are denoted as natural log of the DPM/mg values. **p,0.01.
doi:10.1371/journal.pone.0039243.g004

reports and research data have suggested that coping with stress
and negative mood states is a common motive for use among
heavy abusers [35], which would be consistent with selfmedicating subthreshold anxiety and negative affect induced by
PENK dysfunction. Interestingly, previous studies that have
addressed the self-medication hypothesis showed that cannabis is
more likely to exacerbate mood symptoms than to alleviate them
[36]. Cannabis exposure and negative affect may thus interact in
a complex way within a vicious cycle where cannabis may be used
to cope with subthreshold symptoms, but paradoxically further
increase them in the long term. That our population consisted of
non-depressed subjects underscores the fact that subthreshold
symptoms that are not captured by DSM-IV may well have an
impact on the emergence and course of a clinically significant
disorder such as cannabis dependence.
Another important finding is the role of PENK SNPs in
predicting cannabis dependence. The vulnerability conferred by
PENK (and to a lesser extent DRD2) SNPs may reflect disturbances
of specific neurobiological systems common to these genes. Both
DRD2 and PENK genes are strongly expressed in the striatum and
amygdala, brain regions highly relevant to addiction disorders. A
vast literature has emphasized the role of DRD2 in addiction [37];
but significant evidence also suggests PENK involvement in mood/
reward regulation and anxiety that are often correlated with
alterations of the mesocorticolimbic system [38–40] and the
striatopallidal circuitry in aversive behavior [41]. The amygdala
plays a particularly prominent role in negative mood states and
enkephalinergic neurons in the central amygdala are known to be
critically involved in anxiety and stress responsivity [38,40].
Interestingly, the association detected in the current study between
PENK SNPs and mRNA expression was most pronounced in the
central amygdala. The rs2576573 A allele, observed to be more
frequent in cannabis subjects, was associated with higher PENK
mRNA expression in the central amygdala of the postmortem
population in control subjects. This would seem contrary to
predictions based on animal studies since upregulation of
amygdala PENK mRNA expression predicts heightened anxiolytic
responses and cannabis subjects exhibited more Neuroticism/
anxiety. However, it is important to note that it was not possible to
study mRNA expression in the brains of cannabis users, so whether
the same relationship exists between the A rs2576573 allele and
mRNA expression in cannabis-dependent subjects needs to be
investigated. Nevertheless, the current observation does document

becoming dependent on cannabis even at a young age. Decreased
negative reward/avoidance behavior conferred by DRD2 individual genetic differences has been hypothesized to account for
such vulnerability. While we replicated previous findings showing
a role of DRD2 in negative reward learning [18,19,32], cannabisdependence vulnerability did not appear to be driven by this
association. Instead, the results suggest for the first time to our
knowledge that there are fundamental biological differences driven
by genetic impairments in the opioid system in cannabisdependent individuals compared to those who used the drug but
did not become dependent. The study further revealed that
Neuroticism, in contrast to other traits characteristic of cannabisdependent subjects or compared to reward learning and inhibitory
control performance, significantly mediates the association between functional SNPs of PENK (which we now know are
associated with mRNA expression levels in regions relevant to
negative emotional states) and cannabis dependence. The finding
that cannabis dependence is significantly enhanced in a synergistic
fashion in individuals with both high Neuroticism and risk
genotypes emphasizes the potential important synergistic contribution of negative emotional traits and genetics to vulnerability.
Prevailing theories postulate that addiction vulnerability is
linked to impairment of reward sensitivity and/or inhibitory
control. Recently, genetic polymorphisms have been used to
dissect potential striatal dopamine-receptor involvement in decision-making in relation to positive and negative reinforcement
outcomes [18,19,32]. Our data supports an association of the
DRD2 SNP rs6277 with negative reward performance, but not for
other DRD2 SNPs studied. Other investigations [32] have also
indicated a differential effect of the DRD2 SNPs on behavior that
may relate to the role of these SNPs in modulating DRD2 functions
(i.e., DRD2 binding, density). The ability to replicate previous
studies of the DRD2 rs6277 SNP with avoidance learning
emphasizes the validity of our study population. Moreover, the
overall lack of association between reinforcement learning and
inhibitory control to cannabis dependence either directly or as
mediators suggest that although these behavioral traits are
important to various aspects of addiction, they do not appear to
contribute to cannabis-dependence vulnerability to the same
extent as negative emotional traits.
On the other hand, the central role of Neuroticism in the
association between PENK/DRD2 genes and cannabis-use outcomes in our sample has important implications. Both clinical
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7

June 2012 | Volume 7 | Issue 6 | e39243

Cannabis Dependence, Neuroticism and Proenkephalin

for the first time that PENK mRNA expression, particularly in the
amygdala, directly associates with these polymorphic noncoding
PENK SNPs. The fact though that the entire PENK gene is in
strong LD suggests that the causative mutation still remains to be
identified.
There are a number of limitations that should be considered
when evaluating our findings. The lack of association observed
regarding some SNPs, inhibitory control and negative-reward
sensitivity could be related to the study’s design. The small sample
size may have limited our ability to detect genetic effects in
subgroups based on dependence diagnoses. For example, few
cannabis-dependent individuals carried the A allele of the DRD2
rs6277, so it was not possible to explore behavioral traits in relation
to this SNP. Another factor to consider is the cross-sectional
approach of this study. The acute neurocognitive effects of
cannabis might have affected task performance. While subjects
had at least 2 hours of observed abstinence before performing the
tasks, we cannot exclude the contribution of such confounding
factors and our results should be replicated in settings where
chronology of recent use may be better monitored. The fact that
our sample was drawn from a population without significant
psychiatric comorbidity also opens up the question as to whether
these results may be generalizable to other comorbid subgroups.
Replication of our results in a larger cohort will also be important
to address potential stratification effects. Although not specific to
cannabis dependence, results from the Greek Caucasian population suggest that the association between the PENK SNPs and
Neuroticism could be replicated and generalized to other
populations. An additional issue to address in interpreting the
data is that a large percentage of the cannabis group also smoked
cigarettes; thus, nicotine withdrawal could be a potential confound
to the Neuroticism trait ascribed to cannabis-dependent subjects.

However, study participants did not abstain from nicotine on the
day of testing and behavioral traits were determined within an
hour of the subject’s arrival to reduce potential withdrawal
complications. Moreover, cigarette smoking was not associated
with PENK SNPs in the large Caucasian population; cigarette
smoking is thus unlikely to explain the genetic findings in our
subgroup of cannabis-dependent subjects who also smoked
cigarettes.
Overall, our results further support the role of DRD2 in negative
reward learning, and suggest a central role for Neuroticism as an
endophenotype linking PENK polymorphism to cannabis-dependence vulnerability synergistically amplifying the apparent genetic
risk. Future studies are needed to correlate neurobiological
outcomes with behaviors in animal models and other human
populations. Nonetheless, this study suggests that subthreshold
mood and anxiety symptoms that do not meet criteria for a DSMIV disorder may have serious clinical implications. Prevention and
early intervention approaches that focus on coping strategies
among young individuals genetically prone to Neuroticism may
prove to be helpful, and should be specifically examined in such
populations.
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